pipelines & approvals
Live · refreshes automatically
An acquisition of Rhythm would expand AstraZeneca's rare disease and obesity pipeline, and analysts see potential competing bids.
An oral version of Wegovy beating forecasts gives Novo a needed lift amid intensifying competition with Eli Lilly.
The move pressures drugmakers to shift manufacturing to the US and could raise costs across the pharma supply chain.
Lilly's sales gap highlights its dominance in the fast-growing GLP-1 weight-loss market.
Strong Q3 results let Pfizer lift guidance despite looming patent cliffs and policy pressure on drug pricing.
Advisory backing moves the multi-cancer early detection blood test closer to broader regulatory clearance.
A shifted political landscape could change leverage over most-favored-nation pricing and pharma policy deals.
The lawsuit raises questions about the safety disclosures behind the first approved MASH treatment.
With most-favored-nation pricing already embedded in the sector, analysts see limited policy risk from the Democratic sweep.
Sanders' leverage over FDA appropriations could shape drug pricing and agency oversight provisions.
Specialty distribution profits are carrying the largest US drug distributors amid pressure on core operations.
Emerging data linking GLP-1s to broader health effects could widen the drugs' indications and market.
The approval validates Protagonist's peptide platform and brings milestone revenue alongside its quarterly update.
New drug pricing rules in a major generics market could reshape margins for manufacturers and providers.
The financing signals continued investor appetite for next-generation bispecific therapeutics.
The revenue figure offers a read on commercial traction for the targeted cancer therapy developer.
Investigator support adds pressure on the agency ahead of a decision for the Duchenne muscular dystrophy therapy.
Priority review could shorten the path to market for the combination regimen.
An acceptance decision would start the regulatory clock for the biotech's lead dermatology candidate.
Regulatory alignment clarifies the development path for aTyr's lung disease program as it seeks partnering.
Full enrollment completion sets up near-term data for the company's nasal multiple sclerosis candidate.
CVS's split and Bayer's pricing deliberations reflect broader restructuring and policy pressure in pharma.
Dose escalation progress moves the gene therapy program toward a 2027 data readout.
Partnership support advances Hanmi's effort to compete in the crowded obesity drug field.
Early skin-disease data provides a signal for the company's dermatology candidate.
The quarterly update comes alongside a milestone payment tied to the MIMRYLO approval.
Investors weigh defensive pharma exposure as a haven amid a technology-sector retreat.
The update covers the company's progress on its oncology pipeline and partner-backed programs.
Specialty medicines continue to drive profitability for the largest US distributors.
The quarterly report details clinical and corporate developments for the biotech.
The company's quarterly filing outlines its financial position and pipeline progress.
The request could affect how drug prices are set in Japan's reimbursement system.
The scheduled webcast will cover the eye-disease drug developer's quarterly results.
The trial halt and regulatory consultation raise questions about the candidate's near-term development path.